Bladder Cancer in Women: Risk Factors, Symptoms, Diagnosis, and Treatment

Epidemiology

Bladder cancer is the 4th most common cancer in U.S. women. Incidence rises sharply after age 55.

Major Risk Factors

• Smoking: #1 risk; 3× higher risk vs. never-smokers.
• Occupational chemicals: Aromatic amines (dyes, rubber, leather), arsenic, diesel exhaust.
• Chronic cystitis: Recurrent UTIs, indwelling catheters, schistosomiasis.
• Prior pelvic radiation or cyclophosphamide.
• Family history or genetic syndromes (e.g., Lynch).

Red-Flag Symptoms

• Hematuria (gross or microscopic) — most common presentation.
• Dysuria, urinary frequency, urgency.
• Pelvic or back pain (advanced disease).
• Unexplained weight loss.

Diagnostic Pathway

1. Urinalysis plus urine cytology.
2. Cystoscopy (gold standard for visualization).
3. Transurethral resection of bladder tumor (TURBT) for diagnosis and staging.
4. Imaging (CT urography, MRI) for muscle-invasive disease.

Treatment by Stage

• Non-muscle-invasive (NMIBC): TURBT ± intravesical BCG/chemotherapy (mitomycin, gemcitabine).
• Muscle-invasive (MIBC): Radical cystectomy plus urinary diversion ± neoadjuvant cisplatin-based chemo; trimodal therapy (TURBT plus chemo/RT) for bladder preservation.
• Metastatic: Platinum-based chemo → immune checkpoint inhibitors (pembrolizumab, atezolizumab) → enfortumab vedotin or erdafitinib (FGFR-altered).

Prevention

• Smoking cessation (greatest impact).
• Occupational hygiene (PPE, ventilation).
• Adequate hydration; diet rich in fruits and vegetables.

Early detection via prompt evaluation of hematuria dramatically improves outcomes.